This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



apalutamide (Erleada®)


Reference No. 2450

Publication date:
14/05/2019


Appraisal information

apalutamide (Erleada®) 60 mg tablet


Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 09/05/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, apalutamide (Erleada®) cannot be endorsed for use within NHS Wales in adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM CRPC) who are at high risk of developing metastatic disease
Statement of Advice (SOA)
Download